Table II.
Detection and enumeration of CTCs from patients with non-small cell lung cancer with ALK arrangement.
| Patient | Sex | Age, years | EpCAM+ CTCs | ALK+ CTCs | (ALK+ CTCs)/(FISH+ CTCs), % | FISH+ CTCs | Crizotinib | ALK in tissue biopsy, % |
|---|---|---|---|---|---|---|---|---|
| No. 1 | F | 35 | 5 | 3 | 5 | 58 | Y | 76 |
| No. 2 | F | 82 | Failed | 0 | 0 | 16 | Y | 42 |
| No. 3 | M | 59 | 0 | 0 | 0 | 3 | Y | 32 |
| No. 4 | F | 54 | 2 | 4 | 31 | 13 | N | 48 |
| No. 5 | M | 70 | 7 | 0 | 0 | 15 | Y | 54 |
| No. 6 | M | 62 | 8 | 6 | 46 | 13 | N | 28 |
| No. 7 | F | 76 | 5 | 13 | 9 | 149 | N | 31 |
| No. 8 | M | 51 | 0 | 4 | 17 | 24 | Y | 21 |
| No. 9 | F | 49 | 0 | 1 | 50 | 2 | Y | 33 |
| No. 10 | M | 71 | 1 | 6 | 3 | 177 | Y | 37 |
| No. 11 | M | 51 | 1 | 3 | 33 | 9 | Y | 23 |
| No. 12 | F | 32 | 1 | 0 | 0 | 53 | Y | 18 |
| No. 13 | F | 49 | 1 | 0 | 0 | 130 | Y | 27 |
| No. 14 | F | 50 | 0 | 4 | 4 | 92 | N | 24 |
| No. 15 | F | 51 | 0 | 0 | 0 | 4 | Y | 42 |
| No. 16 | F | 63 | 0 | 1 | 1 | 88 | Y | 34 |
| No. 17 | F | 56 | 0 | 1 | 25 | 4 | Y | 52 |
| No. 18 | M | 71 | 1 | 3 | 50 | 6 | N | 49 |
| No. 19 | F | 66 | 0 | 3 | 2 | 149 | Y | 34 |
| No. 20 | F | 53 | 0 | 10 | 62 | 16 | Y | 60 |
| No. 21 | F | 60 | 0 | 3 | 21 | 14 | N | 80 |
| No. 22 | M | 76 | 0 | 5 | 3 | 197 | N | 73 |
| Mean | 1.5 | 3.2 | 5.7 | 56 | 42 | |||
| Crizotinib treatment and | 2.1 | 4.3 | 49.9 | – | – | |||
| ALK+ CTCs patients (mean) | ||||||||
| No crizotinib treatment and ALK+ CTCs patients (mean) | 5.4 | 7.9 | 69.1 | – | – | |||
| No. 23 | M | 69 | 1 | 0 | 0 | 261 | N | Negative |
All patients underwent anticancer therapy. ALK+, detection of ALK rearrangement signal; FISH+, detection of FISH signal; CTC, circulating tumor cell; ALK, anaplastic lymphoma kinase; FISH, fluorescence in situ hybridization; F, female; M, male; Y, yes; N, no.